- Home
- KROS vs BBNX Comparison
KROS vs BBNX Comparison
Compare KROS & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KROS | BBNX |
|---|---|---|
| Founded | 2015 | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 584.9M | 493.1M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | KROS | BBNX |
|---|---|---|
| Price | $11.71 | $9.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $21.86 | ★ $23.80 |
| AVG Volume (30 Days) | 253.7K | ★ 1.0M |
| Earning Date | 05-06-2026 | 04-21-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 146.00 | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $243,864,000.00 | N/A |
| Revenue This Year | N/A | $34.90 |
| Revenue Next Year | $2,751.79 | $34.63 |
| P/E Ratio | $5.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.42 | $8.80 |
| 52 Week High | $22.55 | $32.71 |
Technical Indicators
Market Signals| Indicator | KROS | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 49.83 | 40.25 |
| Support Level | $10.64 | $9.25 |
| Resistance Level | $12.65 | $11.92 |
| Average True Range (ATR) | 0.47 | 0.60 |
| MACD | 0.10 | -0.09 |
| Stochastic Oscillator | 62.41 | 9.19 |
Price Performance
Historical ComparisonAbout KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.